Ibrunat 140MG Capsule (30’s) is a medication that contains Ibrutinib, a targeted therapy primarily used in the treatment of certain types of blood cancers, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Each capsule contains 140 mg of Ibrutinib, which works by inhibiting Bruton’s tyrosine kinase (BTK), a crucial enzyme in the signaling pathways that promote the survival and proliferation of malignant B cells. This innovative approach helps to disrupt the growth of cancer cells while sparing normal cells, making Ibrunat a vital option in oncology. The capsules are typically prescribed for patients who have relapsed or refractory disease, providing a new avenue for treatment where traditional therapies may have failed. Ibrunat is taken orally, allowing for convenient administration, and is often part of a comprehensive treatment plan tailored to the individual needs of the patient.